Highest-materiality recent filing
BullFrog AI gets Nasdaq extension to Feb 8, 2027 to fix bid price deficiency
On Aug 18, 2026, Nasdaq granted additional 180-day compliance period until Feb 8, 2027 to regain $1.00 bid price.
BullFrog AI regains Nasdaq minimum stockholders' equity compliance
Received Nasdaq notice on April 21, 2026 confirming compliance with $2.5M minimum equity requirement.
BullFrog AI secures first commercial agreement with top 5 pharma; runway into late 2027
First commercial feasibility agreement with a top 5 global pharma for bfLEAP platform in MDD (market >$8B).
BullFrog AI raises $3.45M, now believes it meets Nasdaq equity requirement; avoids delisting
Raised aggregate net proceeds of at least $3.45M from ATM sales and equity line of credit facility.
BullFrog AI signs feasibility agreement with top-5 pharma for MDD target discovery
Agreement with top-5 global pharma (by 2025 revenue) for bfLEAP platform to identify novel drug targets in major depressive disorder (MDD).
BullFrog AI receives Nasdaq delisting notice for failing equity requirement; will request hearing
Nasdaq notified BullFrog AI on Feb 19, 2026 that it failed to meet extension terms for the $2.5M stockholders' equity requirement.
BullFrog AI receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified BullFrog AI on Feb 10, 2026 that common stock bid closed below $1.00 for 30 consecutive business days.
BullFrog AI details 2025 progress, pharma partnerships, and 2026 catalysts
Annual cash burn ~$6.2M; $10M equity line and ATM provide financing flexibility.
BullFrog AI stockholders approve reverse stock split and 750,000 share increase to equity plan
Approved reverse stock split at ratio between 1:2 and 1:15, with Board discretion on final ratio.
BullFrog AI receives Nasdaq extension until Feb 17, 2026 to meet equity requirement
Nasdaq granted BullFrog AI an extension until Feb 17, 2026 to regain compliance with $2.5M minimum stockholders' equity requirement.
BullFrog AI secures $10M equity line with Lincoln Park Capital
Entered purchase agreement with Lincoln Park Capital Fund for up to $10M of common stock over 36 months.
Stockholders' equity of $2,188,110 as of June 30, 2025 falls below Nasdaq's $2.5M minimum requirement.
Bullfrog AI enters collaboration with Eleison to optimize Phase 3 pancreatic cancer trial
Collaboration announced Feb 27, 2025; Bullfrog AI to apply bfLEAP platform to Eleison's glufosfamide Phase 3 trial.
Bullfrog AI CFO Dane Saglio passed away on Dec 7; successor search underway
CFO Dane Saglio died on December 7, 2024; had served since September 2021.
Bullfrog AI raises $3.13M in registered direct offering and private placement
Sold 1,565,000 shares (or pre-funded equivalents) at $2.00/share plus warrants for same number.
Study led by Dr. Lopa Mishra published in Cell Reports provides mechanistic evidence for BF-114 target β2-spectrin (SPTBN1 siRNA) in obesity, MASLD, MASH, and HCC.
Bullfrog AI and Lieber Institute identify novel drug targets for neuropsychiatric disorders
Identified dozens of patient clusters for depression, schizophrenia, and bipolar disorder using bfLEAP AI platform.
Bullfrog AI Appoints Dr. Thomas W. Chittenden as Chief Scientific Officer
Dr. Chittenden appointed CSO effective February 26, 2024.
Bullfrog AI closes $5.7M public offering of stock and warrants
Gross proceeds of approx $5.7M from sale of 1,507,139 shares (or pre-funded warrants) and accompanying warrants.
Bullfrog AI highlights 2023 achievements: $8.4M IPO, first revenue, key partnerships
Completed $8.4M IPO listing on Nasdaq in 2023; maintained low burn rate quarter to quarter.
14 candidates over-expressed in colon tumors identified using TCGA data; 3 are novel, 6 near-novel.
Bullfrog AI enters exclusive data partnership with Lieber Institute for Brain Development
Agreement signed Sep 8, 2023 gives Bullfrog AI access to LIBD's transcriptomic, genomic, epigenomic, and imaging brain data.
BullFrog AI announces USPTO issuance of patent for novel mebendazole prodrugs for cancer treatment
USPTO to issue Patent No. 11,712,435 on Aug 1, 2023, protecting novel prodrugs of mebendazole with improved solubility and oral bioavailability.
Gross proceeds of ~$8.43M from sale of 1,297,318 units at $6.50/unit; each unit includes one share, one tradeable warrant (exercise $7.80), and one non-tradeable warrant (exercise $8.125).
Effective February 15, 2023, Don Elsey, William Enright, and Jason Hanson were appointed to serve as Directors of the Company.
Effective February 15, 2023, Don Elsey, William Enright, and Jason Hanson were appointed to serve as Directors of the Company.
Effective February 15, 2023, Don Elsey, William Enright, and Jason Hanson were appointed to serve as Directors of the Company.
Max materiality 0.80 · Median 0.57 · Most common event other_material